Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated Psychosomatic Care in General Hospital Medicine: An Observational Study of Outcomes in Medically Complex Inpatients.

Journal of the Academy of Consultation-Liaison Psychiatry·2026
Same author

Chronic polydipsia and polyuria as rare renal manifestations of Sjögren's syndrome.

EULAR rheumatology open·2026
Same author

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic review.

Annals of hematology·2026
Same author

Epcoritamab in Richter Transformation: Insights from a Real-World Case Series.

Blood advances·2026
Same author

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Nature medicine·2026
Same journal

[In process].

Medizinische Monatsschrift fur Pharmazeuten·2018
Same journal

[In process].

Medizinische Monatsschrift fur Pharmazeuten·2018
Same journal

[In process].

Medizinische Monatsschrift fur Pharmazeuten·2018
Same journal

[In process].

Medizinische Monatsschrift fur Pharmazeuten·2018
Same journal

[In process].

Medizinische Monatsschrift fur Pharmazeuten·2018
Same journal

[In process].

Medizinische Monatsschrift fur Pharmazeuten·2018
See all related articles

Related Experiment Video

Updated: May 1, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

[The multiple myeloma--current view and perspectives].

Stefan Knop

    Medizinische Monatsschrift Fur Pharmazeuten
    |April 19, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Multiple myeloma (MM) remains incurable, requiring therapy for end-organ damage. Recent advances like proteasome inhibitors improve outcomes, but extramedullary disease (EMD) presents challenges.

    More Related Videos

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    12.5K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
    05:32

    Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

    Published on: January 7, 2019

    6.1K
    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
    10:04

    Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

    Published on: May 1, 2015

    12.5K
    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K

    Area of Science:

    • Hematology
    • Oncology
    • Malignant Plasma Cell Disorders

    Context:

    • Multiple myeloma (MM) is an incurable hematologic malignancy.
    • Therapy is initiated upon the occurrence of end-organ damage.
    • Recent advancements include novel agents such as proteasome inhibitors and immunomodulatory drugs.

    Purpose:

    • To review current therapeutic strategies for multiple myeloma.
    • To highlight challenges in treating patients with extramedullary disease (EMD).
    • To discuss the potential future role of genomic analyses in developing targeted therapies.

    Summary:

    • Despite new treatments like proteasome inhibitors and immunomodulatory drugs, multiple myeloma (MM) remains incurable.
    • Current treatment strategies involve polychemotherapy and continuous therapy to achieve high response rates and disease control.
    • Patients with extramedullary disease (EMD) represent a particularly challenging subgroup requiring further therapeutic innovation.

    Impact:

    • Improved treatment results and disease control in multiple myeloma patients.
    • Identification of extramedullary disease (EMD) as a significant challenge in MM management.
    • Anticipation of future targeted therapies based on genomic analyses for personalized MM treatment.